[{"id":"eebefa81-1645-4e61-b40b-7636aef12cd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012031","created_at":"2025-06-14T13:57:15.769Z","updated_at":"2025-06-14T13:57:15.769Z","phase":"Phase 1/2","brief_title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","source_id_and_acronym":"NCT07012031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ERBB3","pipe":" | ","alterations":" HER-2 overexpression","tags":["KRAS • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/06/2025","start_date":" 06/06/2025","primary_txt":" Primary completion: 06/14/2027","primary_completion_date":" 06/14/2027","study_txt":" Completion: 06/14/2027","study_completion_date":" 06/14/2027","last_update_posted":"2025-06-11"},{"id":"3aba5b38-3db1-4e50-b966-dbbd60ad2e6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863818","created_at":"2025-09-07T01:52:13.355Z","updated_at":"2025-09-07T01:52:13.355Z","phase":"","brief_title":"Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs","source_id_and_acronym":"NCT06863818","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-03-07"},{"id":"1eccb30a-8ad1-4c26-a948-9dcc1f4fa1f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03832855","created_at":"2021-01-18T18:55:29.583Z","updated_at":"2025-02-25T12:27:07.330Z","phase":"Phase 1","brief_title":"Assessing the Immunogenicity of pING-hHER3FL","source_id_and_acronym":"NCT03832855","lead_sponsor":"Herbert Lyerly","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pING-hHER3FL"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-24"},{"id":"dc06b6ac-0a69-4fa1-bf0d-291d63c5c2bc","acronym":"HERTHENA-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06172478","created_at":"2023-12-15T19:20:07.848Z","updated_at":"2025-02-25T13:41:58.738Z","phase":"Phase 2","brief_title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06172478 - HERTHENA-PanTumor01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-21"},{"id":"88ad40d2-3f3c-42ee-9ab2-c0a562d28c8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828069","created_at":"2023-04-25T14:03:34.544Z","updated_at":"2025-02-25T14:09:38.080Z","phase":"Phase 2","brief_title":"A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis","source_id_and_acronym":"NCT05828069","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ERBB3","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ERBB3 mutation","tags":["BRAF • ALK • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ERBB3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"b91c94f1-41f7-4fe2-83f9-441496a86f3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919537","created_at":"2023-06-26T14:09:25.129Z","updated_at":"2025-02-25T15:13:34.765Z","phase":"Phase 1","brief_title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","source_id_and_acronym":"NCT05919537","lead_sponsor":"Hummingbird Bioscience","biomarkers":" ERBB3 • NRG1 • EGF","pipe":" | ","alterations":" NRG1 fusion","tags":["ERBB3 • NRG1 • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • albumin-bound paclitaxel • HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-13"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"2602482f-b076-444a-bfcf-8a98cc85e3b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06099639","created_at":"2023-10-25T19:14:02.621Z","updated_at":"2025-02-25T16:40:20.292Z","phase":"","brief_title":"Medical Access Program for Patritumab Deruxtecan","source_id_and_acronym":"NCT06099639","lead_sponsor":"Daiichi Sankyo","biomarkers":" ERBB3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-06"},{"id":"84d273e3-f912-4f66-80af-054c9469875c","acronym":"TROPION-PanTumor01","url":"https://clinicaltrials.gov/study/NCT03401385","created_at":"2021-01-18T16:47:07.204Z","updated_at":"2025-02-25T14:58:37.689Z","phase":"Phase 1","brief_title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","source_id_and_acronym":"NCT03401385 - TROPION-PanTumor01","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HER-2 expression","tags":["HER-2 • ER • PGR • ERBB3 • CD4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 890","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-03"},{"id":"d51630cc-a526-4c45-ba50-82d026376318","acronym":"U31402-A-J101","url":"https://clinicaltrials.gov/study/NCT02980341","created_at":"2021-01-17T17:33:44.191Z","updated_at":"2025-02-25T16:05:30.233Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT02980341 - U31402-A-J101","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ERBB3","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 expression • ERBB3 positive","tags":["HER-2 • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 expression • ERBB3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Completed","enrollment":" Enrollment 182","initiation":"Initiation: 11/28/2016","start_date":" 11/28/2016","primary_txt":" Primary completion: 08/16/2021","primary_completion_date":" 08/16/2021","study_txt":" Completion: 09/07/2023","study_completion_date":" 09/07/2023","last_update_posted":"2024-10-30"},{"id":"ac428d9a-273b-4d56-88c0-0d08a880a183","acronym":"TUXEDO-3","url":"https://clinicaltrials.gov/study/NCT05865990","created_at":"2024-01-16T19:18:52.062Z","updated_at":"2024-07-02T16:35:03.380Z","phase":"Phase 2","brief_title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","source_id_and_acronym":"NCT05865990 - TUXEDO-3","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • ERBB3 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • ERBB3 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"b43bd831-d20e-49e4-b923-6ad5ee195cf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06361940","created_at":"2024-04-12T13:45:06.917Z","updated_at":"2024-07-02T16:35:09.622Z","phase":"Phase 2","brief_title":"Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer","source_id_and_acronym":"NCT06361940","lead_sponsor":"Medical College of Wisconsin","biomarkers":" EGFR • HER-2 • ERBB3 • ERBB4","pipe":" | ","alterations":" ERBB3 expression • ERBB4 expression","tags":["EGFR • HER-2 • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression • ERBB4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-04-15"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"6ad1964d-0f6f-4cdd-938e-6b965c825842","acronym":"DB-1310-O-1001","url":"https://clinicaltrials.gov/study/NCT05785741","created_at":"2023-03-27T20:03:40.439Z","updated_at":"2024-07-02T16:35:18.020Z","phase":"Phase 1/2","brief_title":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05785741 - DB-1310-O-1001","lead_sponsor":"DualityBio Inc.","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DB-1310"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 04/10/2023","start_date":" 04/10/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-23"},{"id":"cbe988a0-8628-422d-8dff-97ed6ee0e4a4","acronym":"PARAMETer","url":"https://clinicaltrials.gov/study/NCT05620914","created_at":"2022-11-17T14:57:10.919Z","updated_at":"2024-07-02T16:35:19.319Z","phase":"Phase 1","brief_title":"A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases","source_id_and_acronym":"NCT05620914 - PARAMETer","lead_sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","biomarkers":" HER-2 • PGR • ERBB3","pipe":"","alterations":" ","tags":["HER-2 • PGR • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-14"},{"id":"dcd3f303-075d-4fe3-9f59-a898ea289a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222489","created_at":"2024-01-24T18:21:04.062Z","updated_at":"2024-07-02T16:35:21.346Z","phase":"Phase 2","brief_title":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","source_id_and_acronym":"NCT06222489","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-02-01"},{"id":"1ecc2351-4f08-4e50-b996-5f839a75ff4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04699630","created_at":"2021-01-19T20:50:12.272Z","updated_at":"2024-07-02T16:35:22.414Z","phase":"Phase 2","brief_title":"A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer","source_id_and_acronym":"NCT04699630","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" ER • ERBB3","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression • ERBB3 expression","tags":["ER • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression • ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-24"},{"id":"7c08cf87-45ad-4ad1-a2a0-cd9cc9ee571c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05203601","created_at":"2023-12-27T20:17:30.683Z","updated_at":"2024-07-02T16:35:25.088Z","phase":"Phase 1","brief_title":"A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.","source_id_and_acronym":"NCT05203601","lead_sponsor":"Shanghai Institute Of Biological Products","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4","pipe":" | ","alterations":" HER-2 overexpression","tags":["EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-12-27"},{"id":"5b010b67-89ab-4594-ae10-5083f9c9c6fe","acronym":"VALENTINE","url":"https://clinicaltrials.gov/study/NCT05569811","created_at":"2022-10-06T13:55:50.127Z","updated_at":"2024-07-02T16:35:36.270Z","phase":"Phase 2","brief_title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","source_id_and_acronym":"NCT05569811 - VALENTINE","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR • ERBB3","pipe":" | ","alterations":" ER positive • HER-2 negative • ERBB3 expression • PGR positive","tags":["HER-2 • ER • PGR • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ERBB3 expression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • patritumab deruxtecan (U3-1402)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/25/2022","start_date":" 11/25/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2023-09-21"},{"id":"80825c94-3674-4a81-9512-e0927059f4a5","acronym":"SOLTI TOT-HER3","url":"https://clinicaltrials.gov/study/NCT04610528","created_at":"2021-01-19T20:32:21.175Z","updated_at":"2024-07-02T16:35:44.805Z","phase":"Phase 1","brief_title":"A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression","source_id_and_acronym":"NCT04610528 - SOLTI TOT-HER3","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • ERBB3","pipe":" | ","alterations":" ER positive • HER-2 negative • ERBB3 expression","tags":["HER-2 • ER • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 01/30/2022","primary_completion_date":" 01/30/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2023-06-23"},{"id":"a7437321-346d-40a3-ad9b-7749466b632b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02673398","created_at":"2021-01-17T17:30:55.191Z","updated_at":"2024-07-02T16:35:45.421Z","phase":"Phase 2","brief_title":"Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer","source_id_and_acronym":"NCT02673398","lead_sponsor":"City of Hope Medical Center","biomarkers":" ERBB3","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2016","start_date":" 12/02/2016","primary_txt":" Primary completion: 03/12/2020","primary_completion_date":" 03/12/2020","study_txt":" Completion: 09/22/2022","study_completion_date":" 09/22/2022","last_update_posted":"2023-06-16"},{"id":"c5f60531-65fd-4bcb-88b3-780e1307cb1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05512182","created_at":"2022-08-23T14:55:32.104Z","updated_at":"2024-07-02T16:35:45.560Z","phase":"Phase 2","brief_title":"Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression","source_id_and_acronym":"NCT05512182","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2 • ERBB3 • ERBB4","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation","tags":["EGFR • HER-2 • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Nerlynx (neratinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2023-06-15"},{"id":"31c3bbd1-fcc3-4f30-973f-d543a9eab2a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828238","created_at":"2023-04-25T14:03:36.965Z","updated_at":"2024-07-02T16:35:49.661Z","phase":"Phase 1","brief_title":"Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy","source_id_and_acronym":"NCT05828238","lead_sponsor":"Affiliated Hospital of Jiangnan University","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-04-25"},{"id":"9cf35a0d-6589-4c60-9d42-5fee66ab236e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769764","created_at":"2023-03-15T14:02:25.719Z","updated_at":"2024-07-02T16:35:50.990Z","phase":"","brief_title":"A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05769764","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KRAS • ALK • ERBB3","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation","tags":["KRAS • ALK • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation"],"overall_status":"Completed","enrollment":" Enrollment 225","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 04/06/2023","primary_completion_date":" 04/06/2023","study_txt":" Completion: 04/06/2023","study_completion_date":" 04/06/2023","last_update_posted":"2023-04-10"}]